PTT 003
Alternative Names: PTT-003Latest Information Update: 10 Mar 2024
At a glance
- Originator Pyrotech Therapeutics
- Class Plasma expanders; Urologics; Vascular disorder therapies
- Mechanism of Action Pyroptosis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atherosclerosis; Chemotherapy-induced damage; CNS disorders; Kidney disorders
Most Recent Events
- 21 Feb 2024 Early research in Atherosclerosis in China (unspecified route), prior to February 2024 (Pyrotech Therapeutics pipeline, February 2024)
- 21 Feb 2024 Early research in Chemotherapy-induced damage in China (unspecified route), prior to February 2024 (Pyrotech Therapeutics pipeline, February 2024)
- 21 Feb 2024 Early research in CNS disorders in China (unspecified route), prior to February 2024 (Pyrotech Therapeutics pipeline, February 2024)